# Exploring Patient Preference Information in Clinical Research and Decision Models: An Investigative Survey

Martina Di Blasio[1], Zahra Bami[1], Carmen Fava[2], Alessia Visconti[1,*], Ileana Baldi[3,†], Paola Berchialla[1,†]

[1]Center for Biostatistics, Epidemiology, and Public Health, Department of Clinical and Biological Sciences, University of Turin
[2]Department of Clinical and Biological Sciences, University of Turin
[3]Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua

[†]These authors jointly supervised the work
[*]Corresponding author

**Corresponding author:** Alessia Visconti, alessia.visconti@unito.it

**Abstract**

**Background.** There is an increasingly acknowledged role for patients in decision-making processes: this involvement extends to defining care pathways, assessing care quality and advancing healthcare technologies. Patient preferences play a pivotal role in this context, particularly when multiple therapeutic options lack clear distinctions in efficacy.

**Methods.** To investigate the use of patient preference information, we conducted an online survey targeting 46 experts in clinical research, pharmaceutical industry, regulatory affairs, and health technology assessment.

The survey included questions about the frequency of using patient preference information, perceptions of the benefits and challenges of integrating them in decision making, as well as the availability of such data within their respective organizations.

**Results** Patient preference information is routinely used by about 30% of the respondents, who highlighted various challenges and technical difficulties for a more widespread adoption, such as limited patient engagement, difficulty in obtaining reliable preference, and resistance to deviating from traditional practices. Despite this, we observed that about 90% of the respondents is likely to prioritize integrating patient preference information in their future research or decision-making processes.

**Conclusion** There is a growing recognition of the potential benefits of adopting a more patient-centric approach to promote a more effective, equitable, and patient-focused healthcare system, but concerted efforts and investments are necessary to support this effort.

## Introduction

Patients are increasingly recognized as key stakeholders in healthcare decision-making. This shift is evident in three crucial areas: the design of care pathways, the assessment of care quality, and the development and evaluation of healthcare technologies[1–3]. Aligning closely with this patient-centered approach is the concept of Value-Based Healthcare (VBHC), which focuses on delivering the care that matters most to patients while ensuring efficient resource utilization[4], and promises improved health outcomes, cost efficiency and system sustainability[5]. By prioritizing patient-relevant outcomes and cost-effectiveness, VBHC reinforces the importance of patient involvement in healthcare decision-making at both individual and systemic levels[6,7]. Building upon the principles of patient-centered care and VBHC, the integration of patient preferences information becomes critical[8,9], particularly when multiple therapeutic options lack clear distinctions in efficacy. In such scenarios, the patient's perspective on side effect profiles, treatment administration methods, and/or impact

on daily life can be the deciding factor in treatment selection[10]. This ensures that medical decisions align with clinical best practices and consider individual patients' values and lifestyle, likely enhancing treatment adherence, health outcomes, and patient satisfaction[11].
To ensure medical products are developed and evaluated to effectively meet patient needs from conception to market and beyond, and to inform regulatory decisions to ensure approved treatments align with patient needs and desires[12–14], patient preference information must be considered in decision-making throughout the entire medical product life cycle, from early research and development to clinical trials, regulatory decisions, and post-market surveillance[15–17].
In this perspective, a crucial aspect is the utilization of existing knowledge from patient preference studies and its integration into a patient-centered healthcare ecosystem. However, the extent to which healthcare professionals understand and apply this knowledge remains unclear. To investigate the integration of patient preference information into clinical research and new treatments development as well as to explore the awareness, understanding, and interests related to patient preference information, we present here the results of a comprehensive online survey targeting experts in clinical research, the pharmaceutical industry, regulatory affairs, and health technology assessment.

## Materials and Methods

### The survey

The survey, available as **Supplementary Data 1**, was designed to investigate how patient preferences are perceived, utilized and valued. It was administered via Typeform, and was open from April 1st, 2023, to June 30th, 2023. It included 16 questions divided in six key areas: *Frequency of Use*: respondents were asked to indicate how often they incorporate patient preference information in their work, ranging from "never" to "always"; *Perceived Benefits*: the survey explored the perceived advantages of integrating patient preferences, such as improved trial design, enhanced patient recruitment and retention, and more patient-centric outcomes; *Implementation Challenges*: participants were prompted to identify an9d rate the significance of various obstacles to integrating patient preferences, including methodological complexities, resource constraints, and regulatory uncertainties; *Organizational Readiness*: questions assessed the availability and accessibility of patient preference data within respondents' organizations, as well as the existence of processes for incorporating this information; *Current Practices*: the survey inquired about specific ways in which patient preference information is currently being used in respondents' work, such as in protocol design, endpoint selection, or benefit-risk assessments; and *Future Outlook*: respondents were asked about their expectations for the future role of patient preferences in clinical research and treatment development.

### Survey respondents

We used a snowball sampling approach, starting from respondents from SIMeF fellows (https://www.simef.it/). They were then invited to forward the invitation to any colleagues who might be interested in taking part, and those colleagues were asked to do the same, resulting in a total of 47 respondents. To encourage the response rate[18], respondents were remunerated with €10, which they could either receive as an Amazon voucher (n = 24) or donate to the Red Cross (n = 21). Two respondents decided not to receive or donate any remuneration. By returning a completed questionnaire, respondents consented to be included in the study.
No personal information (*e.g.,* age, sex, geographical location) was collected. We included one question to verify that users were paying attention to the questionnaire (*i.e.,* "We want to verify that you are paying attention to the questions in the questionnaire, so we ask you to select the option "three") which disqualified one respondent.

**Statistical analysis**

Descriptive statistics were generated using base R (v 4.4.2). Figures were generated using *ggplot2* (v 2.3.5), *ggsankey* (v 0.0.99999), and *ggsuburst* (v 0.3.0).

Due to the explorative nature of this study, the sample size was not pre-determined, and all the received questionnaires were analyzed. Answers were processed anonymously in aggregate, and in compliance with GDPR regulations.

## Results

### Participant Characteristics

We elicited valid responses from 46 participants hailing from various sectors, including pharmaceutical and biotechnology companies (n = 27, 58.7%), academic and research institutions (n = 6, 13.0%), hospitals and clinics (n = 5, 10.9%), government agencies (n = 2, 4.3%), consulting firms (n = 1, 2.2%) and vendors (n = 1, 2.2%), with respondents also at the intersection between multiple roles (i.*e.,* academic and research and hospitals and clinics, n = 2, 4.3%; pharmaceutical and biotechnology companies and hospitals and clinics, n = 2, 4.3%).

The primary occupational domains encompassed researchers (n = 10, 21.7%), healthcare professionals (n = 9, 19.6%), statisticians (n = 8, 17.4%), quality assurance (n = 3, 6.5%), policy or decision analysts (n = 2, 4.3%), pharmacovigilance experts (n = 2, 4.3%), as well as various management and consultancy roles (n = 11, 23.9%), and a patient advocate (2.2%).

About half of the respondents researched on more than one disease (n = 21, 45.7%), with slightly less than one quarter of them researching on more than three areas (n = 11, 23.9%). Neurological, cardiovascular and oncological diseases were the most active research areas (**Supplementary Figure 1)**, with at least 10 respondents mentioning them, followed by endocrine, respiratory, gastrointestinal and renal diseases, infectious diseases and vaccines, and chronic pain (n respondents ≥ 5).

### Patient preference information: current and future use

Patient preference information within organizations is at best limited, with only 8 respondents reporting it to be at least adequate (17.5%; **Figure 1a**). In line with this observation, most respondents reported using patient preference information only occasionally or not at all (n = 32, 69.6%; **Figure 1b**), though future usage is likely (n = 41, 89.1%; **Figure 1c**). Notably, the lack of availability of patient preference information within one's organization is not a clear indicator of its actual use: 7 out of the 8 respondents whose organizations did not provide any patient preference information still use it at least occasionally (**Figure 1d**), confirming the inclination of using such data when provided by external services (n = 35, 76.1%; **Figure 1e**). We also noted that the current use of patient preference information in research or decision-making processes positively influences future use (**Figure 1d**), highlighting the significance of such data.

### Patient preference information: importance and challenges

Respondents agree that patient preference information could improve the identification of innovative clinical trials endpoints, at least moderately (n = 38, 82.0%, **Figure 2a),** and play a crucial role for the development and commercialization of new treatments and therapies (n = 36, 73.8%, **Figure 2b**), and would always have an impact, even if limited. However, significant ideological and practical challenges remain in effectively incorporating these preferences into practice, mostly due to the resistance to innovation, and limited patient engagement, with the consequent difficulty in obtaining preference data (**Figure 2c** and **2d**). Interestingly, lack of time and/or budget and the necessity of additional work represent only a small challenge for the use of patient preference information in the clinical trials design, but not in the decision-making process.




**Figure 1. Patient Preference Information: Use in Research and Development.** The bar plots in the upper panel show the distribution of responses regarding the (a) current availability and (b) usage of patient preference information as well as (c) the likelihood of a future usage, with the (d) Sankey plot showing the flow of answers between these three topics. The bar plot on the bottom panel (e) shows the distribution of responses regarding the desire for external service providers supplying patient preference information. In the bar plots, the x-axes show absolute frequencies, with relative frequencies being reported beside each bar. All represented questions allowed a single answer.




**Figure 2. Patient Preference Information: Importance and Challenges in Research and Development.** The bar plots show the distribution of responses regarding the importance of patient preference information in (a) the design and outcomes of clinical trials and (b) development and commercialization of new treatments and therapies as well as the challenges that researchers predict facing by including them in (c) clinical trials design and (d) decision-making. The x-axes show absolute frequencies. The questions presented in the upper panels allowed a single answer, and their relative frequencies are reported beside each bar. The questions presented in the bottom panel allowed multiple answers, and their total absolute frequencies are reported beside each bar.

**Patient preference information: possible applications**

When asked on possible avenues for the use of patient preference information by different stakeholders, we gathered a plethora of suggestions. Academic institutions and researchers could employ such information to enhance the design of clinical studies, better identify patients' medical needs, improve forecasting, assess the qualitative performance of procedures from patients' perspectives, improve doctor-patient relationships and treatment adherence, and support treatment decisions even in scenarios where patients are unable to decide autonomously. Health Technology Assessment (HTA) agencies could utilize patient preference information to evaluate the impact of treatments on patients' needs, support reimbursement decisions, expedite approval of new products aligning with patient preferences and evaluate patient preference for various treatment options. Pharmaceutical and biotechnology companies could use patient preference information to refine product profiles, enhance compliance with clinical studies, optimize protocol design, increase patient satisfaction and develop treatments or medical devices aligned with patients' needs. Government agencies could employ patient preference information to improve quality of life, support reimbursement decisions, guide the introduction of new technologies, enhance healthcare services, evaluate the performance of healthcare providers, provide research support, inform and facilitate approval of treatments/medical devices, and assess cost-effectiveness of medical interventions to enhance health insurance plans.

**Discussions**

Understanding and incorporating patients' values, priorities, and trade-offs in healthcare decision-making, also recognizing that truly effective personalized care, which goes beyond clinical outcomes, has become a crucial aspect of developing and evaluating medical products[9,11,12]. However, data on the integration of patient preference information in clinical research and the development of new treatments is lacking.

Here, by using data collected across various stakeholder groups, we observed that, while half of respondents expressed an inclination to prioritize the integration of such data in their future research projects, the overall current utilization rates are suboptimal, with 26% of respondents reporting that they never employ patient preference information and an additional 44% doing so only occasionally. This is in line with previous observations that effectively incorporating patient preferences into healthcare delivery and product development presents its own set of challenges[19–21], such as developing reliable methods for eliciting and measuring preferences across diverse patient populations, integrating preference data into clinical decision-making tools and regulatory processes, and balancing individual preferences with evidence-based practices and resource constraints. We confirmed here that limited patient engagement and difficulty in obtaining reliable preference data are major obstacles in the integration of patient preference information. Additionally, half of the participants cited the resistance to deviating from traditional practices as a significant barrier, suggesting the need for a mindset shift for this novel approach. It has already been recognized that traditional evaluation methods prioritize quantitative data and economic metrics, especially when resources are limited, and financial considerations may overshadow the need for a patient-centered approach[19]. Stereotypes and biases regarding the value of patient opinions further complicate this issue: many professionals may perceive patient preferences as subjective or less relevant compared to clinical data and scientific evidence[20]. We argue here that more training and larger exposure to effective patient engagement practices may be needed to foster a more open mindset.

Concerns regarding the potential introduction of bias and the lack of standardized data collection methodologies further stress the need for rigorous and well-established frameworks. A first and especially important step in this direction is the IMI-PREFER project[9], which developed a robust

framework that outlines the methodology for conducting patient preference studies[22], including guidelines for study design[23,24], and stakeholder interaction[14]. One of its key aspects is standardizing the methods used to collect and analyze patient preference data, including defining qualitative and quantitative techniques and creating templates and guidelines for conducting studies in diverse disease areas[25]. Further efforts in creating such framework have resulted in the Patient-Centered Outcomes Research Institute's (PCORI) methodology standards[25]. However, for these frameworks to be widely adopted, we believe broader collaboration across stakeholders and increasing training on best practices are needed. Moreover, regulatory bodies, such as the US Food and Drug Administration and the European Medicines Agency, should include these guidelines within their own frameworks.

Notably, the inadequate availability of aggregated preference data within organizations emerged as a significant barrier. Sixty-five percent of respondents reported limited availability, while 17% indicated a complete lack of such data. This suggests a need for concerted efforts and investments to establish reliable data repositories and make patient preference information readily accessible, including data from external providers, as evidenced by 76% of participants expressing interest in using them if provided.

Despite these challenges, about 90% of the respondents expressed at least a mild inclination to prioritize integrating patient preference information in their future research or decision-making processes. This positive outlook reflects a growing recognition of the potential benefits of adopting a more patient-centric approach in future research or decision-making processes. Furthermore, respondents' direct experiences provided various applications of aggregated patient preference data by different entities, including academic institutions and researchers, HTA agencies, pharmaceutical, biotechnology companies and government agencies, with the general recognition that using these data shows potential for improving healthcare quality, advancing personalized treatment, guiding healthcare policy and reimbursement choices, in line with previous observation[26–28].

While our study provides a much-needed overview of the current state of utilizing patient preferences in clinical research and decision-making processes, it is important to note that our findings may have underlying bias due to the relatively small sample size. Further research involving larger and more diverse populations is necessary to validate and generalize our findings.

In summary, while the adoption of patient preference information remains limited, there is a growing recognition of its potential benefits and increasing interest in integrating it into future processes, despite existing challenges and disparities in the utilization rates across organizations and stakeholder groups. Incorporating patient preferences into clinical research and decision-making can not only improve study design and outcomes, but also strengthen patient engagement, and ensure that new treatments better meet their needs and priorities. To fully realize the value of patient preferences, concerted efforts are needed to overcome identified challenges, such as resistance to change, limited patient participation, lack of standardization and the availability of high-quality data. A patient-centered approach is essential for promoting a more effective, equitable and patient-focused healthcare system.

**Ethics approval**

Ethics committee consent was unnecessary since the authors used data which were anonymizes before the analysis was performed, and did not collect any sensitive information. Individuals cannot be identified directly or through identifiers. Ethics committee of the University of Turin (Comitato di Bioetica d'Ateneo) waived ethical approval for this work (Protocol number 0722874).

**Conflicts of interest**
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject or materials discussed in this manuscript.

**Authors' contributions**
MdB, IB, and PB conceptualized and designed the project. MdB, CF, IB, and PB designed the survey. MdB, AV and PB carried out the statistical analyses with contributions from ZB. AV created the figures. MdB, AV, IB, and PB interpreted the results. MdB, AV, and PB wrote the manuscript. All authors read and approved the final manuscript.

**Funding**
This work was partially supported by "NODES Spoke 5 project" no ECS00000036, which has received funding from MUR-M4C2 1.5 of PNRR (code BERP_PNRR_EI_23_01_F). This work was partially supported by the "Proof of Value Instrument 2022 Initiative" (S1921_POV_D218) funded by Compagnia San Paolo and University of Turin.

**Data availability**
Data collected during the study are available to *bona fide* researchers under managed access due to governance constraints, and can be requested to the corresponding author.

## References

1. Greenhalgh, T. *et al.* Beyond Adoption: A New Framework for Theorizing and Evaluating Nonadoption, Abandonment, and Challenges to the Scale-Up, Spread, and Sustainability of Health and Care Technologies. *J. Med. Internet Res.* **19**, e367 (2017).
2. Coulter, A. Measuring what matters to patients. *BMJ* **356**, j816 (2017).
3. Bombard, Y. *et al.* Engaging patients to improve quality of care: a systematic review. *Implement. Sci. IS* **13**, 98 (2018).
4. Teisberg, E., Wallace, S. & O'Hara, S. Defining and Implementing Value-Based Health Care: A Strategic Framework. *Acad. Med. J. Assoc. Am. Med. Coll.* **95**, 682–685 (2020).
5. Salvatore, F. P., Fanelli, S., Donelli, C. C. & Milone, M. Value-based health-care principles in health-care organizations. *Int. J. Organ. Anal.* **29**, 1443–1454 (2021).
6. Lansdaal, D., Van Nassau, F., Van Der Steen, M., Bruijne, M. D. & Smeulers, M. Lessons learned on the experienced facilitators and barriers of implementing a tailored VBHC model in a Dutch university hospital from a perspective of physicians and nurses. *BMJ Open* **12**, e051764 (2022).
7. van Staalduinen, D. J. *et al.* The implementation of value-based healthcare: a scoping review. *BMC Health Serv. Res.* **22**, 270 (2022).
8. US Food and Drug Administration. *Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and*

*De Novo Requests, and Inclusion in Decision Summaries and Device Labeling*. https://www.federalregister.gov/d/2016-20221 (2016).

9. Smith, I. P. *et al.* Methodological Priorities for Patient Preferences Research: Stakeholder Input to the PREFER Public–Private Project. *Patient - Patient-Centered Outcomes Res.* **14**, 449–453 (2021).
10. Losi, S. *et al.* The role of patient preferences in adherence to treatment in chronic disease: a narrative review. *Drug Target Insights* **15**, 13–20 (2021).
11. Pauker, S. G. & McNeil, B. J. Impact of patient preferences on the selection of therapy. *J. Chronic Dis.* **34**, 77–86 (1981).
12. Levitan, B. *et al.* Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. *Ther. Innov. Regul. Sci.* **52**, 220–229 (2018).
13. Janssens, R. *et al.* How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action. *Front. Pharmacol.* **14**, 1192770 (2023).
14. Hiligsmann, M. *et al.* HTA community perspectives on the use of patient preference information: lessons learned from a survey with members of HTA bodies. *Int. J. Technol. Assess. Health Care* **40**, e17 (2024).
15. Whichello, C. *et al.* An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process? *Health Policy* **124**, 1325–1332 (2020).
16. Van Overbeeke, E., Vanbinst, I., Jimenez-Moreno, A. C. & Huys, I. Patient Centricity in Patient Preference Studies: The Patient Perspective. *Front. Med.* **7**, 93 (2020).
17. Zhang, L., Li, D., Li, X. & Yan, J. Patient preferences for generic substitution policies: a discrete choice experiment in China. *Front. Pharmacol.* **15**, 1400156 (2024).
18. Abdelazeem, B. *et al.* Does usage of monetary incentive impact the involvement in surveys? A systematic review and meta-analysis of 46 randomized controlled trials. *PLOS ONE* **18**, e0279128 (2023).
19. Huls, S. P. I., Whichello, C. L., van Exel, J., Uyl-de Groot, C. A. & de Bekker-Grob, E. W. What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the

Challenges. *Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.* **22**, 1318–1328 (2019).

20. Janssens, R. *et al.* Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. *BMC Med. Inform. Decis. Mak.* **19**, 189 (2019).
21. Janssens, R. *et al.* Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. *Patient - Patient-Centered Outcomes Res.* **12**, 513–526 (2019).
22. Soekhai, V. *et al.* Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. *Drug Discov. Today* **24**, 1324–1331 (2019).
23. Whichello, C. *et al.* Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. *BMC Med. Inform. Decis. Mak.* **20**, 114 (2020).
24. Veldwijk, J. *et al.* Suitability of Preference Methods Across the Medical Product Lifecycle: A Multicriteria Decision Analysis. *Value Health* **26**, 579–588 (2023).
25. Gaglio, B. *et al.* Methodological standards for qualitative and mixed methods patient centered outcomes research. *BMJ* m4435 (2020) doi:10.1136/bmj.m4435.
26. Van Overbeeke, E. *et al.* Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. *Front. Pharmacol.* **10**, 1395 (2019).
27. Chachoua, L. *et al.* Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives. *Front. Med.* **7**, 543046 (2020).
28. Marsh, K., De Bekker-Grob, E., Cook, N., Collacott, H. & Danyliv, A. How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations. *Int. J. Technol. Assess. Health Care* **37**, e75 (2021).